Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
Trevi Therapeutics (Nasdaq: TRVI) reported promising results from a mid-stage study of its experimental chronic cough ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...
Trevi Therapeutics, Inc. (NASDAQ:TRVI) reported topline results from its Phase 2a RIVER trial of Haduvio (oral nalbuphine ER) ...
New Haven, Connecticut Tuesday, March 11, 2025, 18:00 Hrs [IST] ...
Trevi Therapeutics (TRVI) announced topline results from its Phase 2a RIVER trial of Haduvio for the treatment of patients with RCC. Haduvio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results